Charlotte Becker
Titel
Docent
Organisation
+4640332227
Charlotte [dot] Becker [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2012
- Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
- prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk.
- 2011
- 2010
- C-peptide in dried blood spots.
- Circadian variation in concentration of anti-Mullerian hormone in regularly menstruating females - relation to age, gonadotrophin and steroid levels
- Comparison of measurements of autoantibodies to glutamic acid decarboxylase and islet antigen-2 in whole blood eluates from dried blood spots using the RSR-enzyme linked immunosorbent assay kits and in-house radioimmunoassays.
- Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
- Toward Next Generation Plasma Profiling via Heat-induced Epitope Retrieval and Array-based Assays
- 2008
- A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits.
- A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden
- Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population
- Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
- 2007
- 2006
- Increase of bioavailable testosterone is associated with gain in bone mineral density after cure of primary hyperparathyroidism in postmenopausal women
- Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism
- Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C.
- Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hk2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
- 2005
- Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
- Macro/Nano-Structured Silicon as Solid Support for Antibody Arrays: Surface Design, Reproducibility, and Assay Characteristics Enabling Discovery of Kallikrein Gene Products for Prostate Disease Diagnostics
- 2004
- Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio
- Early parathyroidectomy increases bone mineral density in patients with mild primary hyperparathyroidism: A prospective and randomized study
- Integrated selective enrichment target - a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases
- 2003
- Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
- Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
- Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
- Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
- The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer
- Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
- 2001
- Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis
- Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml
- The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease
- Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level
- 2000
- Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater
- Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
- Human glandular kallikrein 2 (hK2) in prostate cancer: Clinical and Methodological studies
- Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer
- Sensitive and specific immunodetection of human glandular kallikrein 2 in serum
- Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues
- Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden
- 1999
- Characterization of epitope structure for 53 monoclonal antibodies against prostate-specific antigen
- Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
- Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen
- 1998
- 1997
